Although it’s unclear precisely how anticholinergic medications impact the brain, this research isn’t the first to associate them with an increased risk of dementia.
According to earlier research, oxybutynin, which is marketed under the names Aspire, Ditropan, and Kentera, may pose a special danger since its molecules are smaller than those of other forms.
Experts claim that this makes it possible for it to get deeper into the brain and impact the delicate tissues there more powerfully.
About 110,000 oxybutynin prescriptions are written each month at a cost to taxpayers of about 15p per tablet, according to statistics from OpenPrescribing, an NHS-backed data source.
A variety of degenerative illnesses that affect memory, thinking, and behavior are together referred to as dementia.
